Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,779 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma.
Tanaka Y, Nakasone H, Yamazaki R, Sato K, Sato M, Terasako K, Kimura S, Okuda S, Kako S, Oshima K, Tanihara A, Nishida J, Yoshikawa T, Nakatsura T, Sugiyama H, Kanda Y. Tanaka Y, et al. Among authors: yoshikawa t. Cancer Res. 2010 Aug 1;70(15):6181-92. doi: 10.1158/0008-5472.CAN-10-0678. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647322
HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S, Nakatsura T. Yoshikawa T, et al. Cancer Sci. 2011 May;102(5):918-25. doi: 10.1111/j.1349-7006.2011.01896.x. Epub 2011 Mar 4. Cancer Sci. 2011. PMID: 21281401 Free PMC article. Clinical Trial.
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, Ishii H, Furuse J, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T, Komori H, Baba H, Fujiwara T, Nakatsura T. Nobuoka D, et al. Among authors: yoshikawa t. Int J Oncol. 2012 Jan;40(1):63-70. doi: 10.3892/ijo.2011.1202. Epub 2011 Sep 15. Int J Oncol. 2012. PMID: 21922136 Clinical Trial.
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Sawada Y, et al. Among authors: yoshikawa t. Clin Cancer Res. 2012 Jul 1;18(13):3686-96. doi: 10.1158/1078-0432.CCR-11-3044. Epub 2012 May 10. Clin Cancer Res. 2012. PMID: 22577059 Clinical Trial.
Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy.
Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T. Nobuoka D, et al. Among authors: yoshikawa t. Cancer Immunol Immunother. 2013 Apr;62(4):639-52. doi: 10.1007/s00262-012-1366-6. Epub 2012 Nov 11. Cancer Immunol Immunother. 2013. PMID: 23143746 Free PMC article.
4,779 results